Investor Relations

Press Releases

Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting

Read More

Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)

Read More

Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer

Read More

Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer

Read More

Advaxis to Present at the Jefferies Immuno-Oncology Summit

Read More

Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

Read More

Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting

Read More

Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients

Read More

Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial

Read More

Advaxis to Present at the 27th Annual ROTH Conference

Read More